Frog Bacterium Wipes Out Cancer Tumors in Mice with One Dose
A single injection of a frog-derived bacterium eliminated colorectal tumors in mice, outperforming chemo and immunotherapy.
Summary
Scientists at Japan's JAIST discovered that a bacterium from Japanese tree frog intestines can completely eliminate colorectal cancer tumors in mice with a single intravenous dose. The bacterium, Ewingella americana, achieved a 100% complete response rate in the mouse model, outperforming standard treatments including immune checkpoint inhibitors and chemotherapy. It works through two mechanisms: multiplying inside oxygen-deprived tumor tissue and activating immune cells like T cells, B cells, and neutrophils to attack cancer. Crucially, the bacteria concentrated almost exclusively in tumors and avoided healthy organs, suggesting a favorable safety profile. While results are limited to mice, researchers believe this living bacterial therapy could one day be adapted to treat many types of solid tumors in humans.
Detailed Summary
Researchers at the Japan Advanced Institute of Science and Technology have identified a naturally occurring bacterium from Japanese tree frog intestines that eliminates colorectal cancer tumors in mice with a single treatment. Published in Gut Microbes, the study introduces a novel approach to cancer therapy using live bacteria delivered directly into the bloodstream to attack tumors from within.
The bacterium, Ewingella americana, was screened from 45 strains collected from amphibian and reptile intestines. In a mouse model of colorectal cancer, a single intravenous dose achieved a 100% complete response rate, meaning all treated tumors were fully eliminated. This result surpassed both anti-PD-L1 immune checkpoint inhibitors and the chemotherapy drug liposomal doxorubicin in head-to-head comparisons.
The treatment works through two complementary mechanisms. First, E. americana thrives in low-oxygen environments — conditions common inside tumor cores — and multiplied roughly 3,000-fold within 24 hours of injection, directly damaging cancer cells. Second, the bacteria triggered a robust immune response, recruiting T cells, B cells, and neutrophils into the tumor and stimulating release of inflammatory signals like TNF-α and IFN-γ that promote cancer cell death.
A key finding was the bacteria's remarkable tumor specificity. E. americana accumulated almost exclusively in tumor tissue and avoided healthy organs. This selectivity appears to result from tumors' leaky blood vessels, low oxygen levels, immune-suppressing CD47 protein expression on cancer cells, and unique metabolic conditions — all of which favor bacterial colonization in tumors but not normal tissue.
Importantly, these findings are confined to mouse models and have not yet been tested in humans. Significant work remains before clinical translation, including safety validation across diverse cancer types and species. Nevertheless, this proof-of-concept represents a potentially transformative platform for living bacterial cancer therapies.
Key Findings
- Single intravenous dose of E. americana achieved 100% tumor elimination in a mouse colorectal cancer model.
- The bacterium outperformed both immune checkpoint inhibitor anti-PD-L1 and chemotherapy drug liposomal doxorubicin.
- E. americana multiplied ~3,000-fold inside tumors within 24 hours by exploiting low-oxygen tumor environments.
- Bacteria accumulated almost exclusively in tumor tissue, sparing healthy organs in safety evaluations.
- Dual mechanism: direct tumor cell damage plus immune activation via T cells, B cells, and neutrophils.
Methodology
This is a research summary based on a peer-reviewed study published in Gut Microbes from a credible academic institution, JAIST. Evidence is based on in vivo mouse model experiments with controlled comparisons to standard cancer therapies. The article is a news report summarizing primary research findings.
Study Limitations
All results are from mouse models only and have not been tested in humans; clinical translation may face significant safety and regulatory hurdles. The article is truncated and full safety data were not completely reported. Independent replication in additional cancer types and animal models is needed before drawing conclusions about human applicability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: